Elicio Therapeutics, a Cambridge, Mass.-based biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, closed a $73m Series B financing.
The company intends to use the funds to advance its lead program ELI-002 into clinical trials in early 2021 for mutated KRAS (mKRAS) driven cancers, estimated to be 25% of all human solid tumors.
Led by Robert Connelly, CEO, Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer, Elicio Therapeutics is advancing the Amphiphile technology across immunotherapy platforms to defeat cancers and infectious diseases. The company is engineering lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases. Its lead Amphiphile vaccine, ELI-002, targeting KRAS-driven cancers will begin initial patient studies in solid tumor patients in the first quarter of 2021. The Amphiphile platform emerged from laboratories of Darrell Irvine, Howard Hughes Investigator and Professor of Biomedical Engineering in the Koch Institute of Integrative Cancer Research at MIT.
ELI-002 contains two components: the company’s proprietary immune stimulating Amphiphile (AMP)-CpG, an adjuvant, and AMP mKRAS peptides which target a broad spectrum of KRAS mutations that drive 97% of all KRAS-driven cancers.
ELicio has collaborations with top institutions such as MIT, National Cancer Institute, Moffitt Cancer Center, Boston Children’s Hospital, and QIMR Berghofer Medical Research Institute, advancing the AMP platform, AMP cell therapies, therapeutic vaccines, prophylactic vaccines and adjuvants to the clinic and expect to expand our commercial partnership base.